<?xml version="1.0" encoding="UTF-8"?>
<p id="Par5">Nasopharyngeal carcinoma (NPC) is highly endemic in Southern China and Southeast Asia, with a peak incidence of 50 cases per 100,000 [
 <xref ref-type="bibr" rid="CR1">1</xref>]. Concurrent chemoradiotherapy (CCRT) with or without adjuvant chemotherapy is currently considered as the standard therapeutic regimen for locoregionally advanced NPC [
 <xref ref-type="bibr" rid="CR2">2</xref>–
 <xref ref-type="bibr" rid="CR6">6</xref>]. A previous study from this research group [
 <xref ref-type="bibr" rid="CR7">7</xref>] demonstrated that induction chemotherapy with cisplatin, fluorouracil, and docetaxel in addition to CCRT significantly improved survival versus CCRT alone for advanced NPC patients. However, the role of induction chemotherapy remains debatable. Currently, experts agree that concurrent use of cisplatin with radiation improves progression-free survival (PFS) and overall survival (OS) [
 <xref ref-type="bibr" rid="CR6">6</xref>, 
 <xref ref-type="bibr" rid="CR8">8</xref>–
 <xref ref-type="bibr" rid="CR11">11</xref>].
</p>
